These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 27879554)

  • 1. Measles and Rubella Seroprevalence Among HIV-infected and Uninfected Zambian Youth.
    Sutcliffe CG; Searle K; Matakala HK; Greenman MP; Rainwater-Lovett K; Thuma PE; Moss WJ
    Pediatr Infect Dis J; 2017 Mar; 36(3):301-306. PubMed ID: 27879554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Seroprevalence of antibodies to measles, mumps, and rubella, and serologic responses after vaccination among human immunodeficiency virus (HIV)-1 infected adults in Northern Thailand.
    Chaiwarith R; Praparattanapan J; Nuket K; Kotarathitithum W; Supparatpinyo K
    BMC Infect Dis; 2016 Apr; 16():190. PubMed ID: 27138005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measles immunity gaps among children and adolescents with HIV in Zambia despite high measles vaccination and antiretroviral therapy coverage.
    Mutembo S; Yang Y; Carcelen A; Winter AK; Mwansa FD; Chilumba I; Mutale I; Chongwe G; Monze M; Mulundu G; Nkamba H; Mulenga L; Hayford K; Moss WJ
    AIDS; 2023 Nov; 37(13):2021-2029. PubMed ID: 37418463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measles and rubella serosurvey identifies rubella immunity gap in young adults of childbearing age in Zambia: The added value of nesting a serological survey within a post-campaign coverage evaluation survey.
    Hayford K; Mutembo S; Carcelen A; Matakala HK; Munachoonga P; Winter A; Wanyiri JW; Searle K; Mwansa FD; Mwiche A; Phiri C; Book C; Thuma PE; Moss WJ
    Vaccine; 2019 Apr; 37(17):2387-2393. PubMed ID: 30905529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of a Measles and Rubella Vaccination Campaign on Seroprevalence in Southern Province, Zambia.
    Carcelen AC; Mutembo S; Matakala KH; Chilumba I; Mulundu G; Monze M; Mwansa FD; Moss WJ; Hayford K
    Am J Trop Med Hyg; 2021 May; 104(6):2229-2232. PubMed ID: 33939639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in measles serostatus among HIV-infected Zambian children initiating antiretroviral therapy before and after the 2010 measles outbreak and supplemental immunization activities.
    Rainwater-Lovett K; Nkamba HC; Mubiana-Mbewe M; Bolton-Moore C; Moss WJ
    J Infect Dis; 2013 Dec; 208(11):1747-55. PubMed ID: 23911708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Seroprevalence of measles, mumps & rubella antibodies among 5-10 years old children in north India.
    Gupta M; Tripathy JP; Verma M; Singh MP; Kaur R; Ratho RK; Kumar R
    Indian J Med Res; 2019 Mar; 149(3):396-403. PubMed ID: 31249206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age-stratified seroprevalence of measles, mumps and rubella (MMR) virus infections in Switzerland after the introduction of MMR mass vaccination.
    Matter L; Germann D; Bally F; Schopfer K
    Eur J Epidemiol; 1997 Jan; 13(1):61-6. PubMed ID: 9062781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leveraging a national biorepository in Zambia to assess measles and rubella immunity gaps across age and space.
    Carcelen AC; Winter AK; Moss WJ; Chilumba I; Mutale I; Chongwe G; Monze M; Mulundu G; Nkamba H; Mwansa FD; Mulenga L; Rhoda DA; Hayford K; Mutembo S
    Sci Rep; 2022 Jun; 12(1):10217. PubMed ID: 35715547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of immune status against measles, mumps, and rubella in young Kuwaitis: MMR vaccine efficacy.
    Madi N; Altawalah H; Alfouzan W; Al-Nakib W; Al-Roumi E; Jeragh A
    J Med Virol; 2020 Aug; 92(8):963-970. PubMed ID: 31919861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seroprevalence of Measles, Mumps, and Rubella Antibodies in College Students in Mumbai, India.
    Gohil DJ; Kothari ST; Chaudhari AB; Gunale BK; Kulkarni PS; Deshmukh RA; Chowdhary AS
    Viral Immunol; 2016 Apr; 29(3):159-63. PubMed ID: 26910764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Seroprevalence of measles and rubella antibodies in pregnant women Haiti, 2012.
    Fitter DL; Anselme R; Paluku G; Rey G; Flannery B; Tohme RA; Marston BJ; Griswold M; Boncy J; Vertefeuille JF
    Vaccine; 2013 Dec; 32(1):69-73. PubMed ID: 24188751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measles immunity gap among reproductive-age women participating in a simulated HIV vaccine efficacy trial in Zambia.
    Malama K; Tichacek A; Kelly H; Parker R; Inambao M; Sharkey T; Wall KM; Kilembe W; Price MA; Fast P; Priddy F; Allen S
    Hum Vaccin Immunother; 2022 Nov; 18(5):2066426. PubMed ID: 35446726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Seroprevalence of vaccine-preventable and non-vaccine-preventable infections in migrants in Spain.
    Norman FF; Comeche B; Martínez-Lacalzada M; Pérez-Molina JA; Gullón B; Monge-Maillo B; Chamorro S; López-Vélez R
    J Travel Med; 2021 Jun; 28(4):. PubMed ID: 33611577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiology of acute rubella infection in Zambia during the pre-vaccination period (2005-2016) as a baseline for monitoring rubella epidemiology in the post-rubella vaccine introduction era.
    Mazaba ML; Siziya S; Monze M; Cohen D
    BMC Infect Dis; 2020 Feb; 20(1):101. PubMed ID: 32013873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Seroprevalence of measles, mumps, rubella, and varicella zoster virus antibodies among healthcare students: analysis of vaccine efficacy and cost-effectiveness.
    Ödemiş Í; Köse Ş; Akbulut Í; Albayrak H
    Rev Esp Quimioter; 2019 Dec; 32(6):525-531. PubMed ID: 31642641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Seroprevalence of measles, mumps and rubella among young adults, after 20 years of universal 2-dose MMR vaccination in Israel.
    Levine H; Zarka S; Ankol OE; Rozhavski V; Davidovitch N; Aboudy Y; Balicer RD
    Hum Vaccin Immunother; 2015; 11(6):1400-5. PubMed ID: 25891446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Seroprevalence of measles IgG among HIV-1-infected and uninfected Kenyan adults.
    Merkel M; Ben-Youssef L; Newman LP; Gitome V; Gataguta A; Lohman-Payne B; Bosire R; Farquhar C
    Int J Infect Dis; 2014 Feb; 19():103-5. PubMed ID: 24334025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measles and rubella IgG seroprevalence in persons 6 month-35 years of age, Mongolia, 2016.
    Nogareda F; Gunregjav N; Sarankhuu A; Munkhbat E; Ichinnorov E; Nymadawa P; Wannemuehler K; Mulders MN; Hagan J; Patel MK
    Vaccine; 2020 May; 38(26):4200-4208. PubMed ID: 32381479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early loss of measles antibodies after MMR vaccine among HIV-infected adults receiving HAART.
    Belaunzarán-Zamudio PF; García-León ML; Wong-Chew RM; Villasís-Keever A; Cuellar-Rodríguez J; Mosqueda-Gómez JL; Muñoz-Trejo T; Escobedo K; Santos JI; Ruiz-Palacios GM; Sierra-Madero JG
    Vaccine; 2009 Nov; 27(50):7059-64. PubMed ID: 19799846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.